Neurocrine Biosciences
NBIX
426 hedge funds and large institutions have $8.35B invested in Neurocrine Biosciences in 2022 Q1 according to their latest regulatory filings, with 68 funds opening new positions, 161 increasing their positions, 145 reducing their positions, and 43 closing their positions.
58% more first-time investments, than exits
New positions opened: 68 | Existing positions closed: 43
13% more call options, than puts
Call options by funds: $89.6M | Put options by funds: $79.5M
11% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 145
10% more capital invested
Capital invested by funds: $7.57B → $8.35B (+$780M)
5% more funds holding
Funds holding: 405 → 426 (+21)
0.87% more ownership
Funds ownership: 93.98% → 94.86% (+0.87%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$61.4M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
+$56.8M |
| 3 |
AC
Armistice Capital
New York
|
+$55.1M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$40.3M |
| 5 |
Two Sigma Advisers
New York
|
+$36.9M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$96.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$61.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$36.9M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$33.6M |
| 5 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$33.1M |
NBIX Hedge Fund Activity: Q1 2022 in Review
426 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2022, worth a combined $8.35B — up 10% from $7.57B a quarter earlier.
Buyers outnumbered sellers: 68 funds opened new NBIX positions and 43 closed out — a net gain of 25 holders — while 161 added to existing stakes and 145 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $61.4M. The largest seller was Janus Henderson Group, cutting an estimated $96.3M.
- 426 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2022, up from 405 in Q4 2021.
- Funds reported $8.35B of Neurocrine Biosciences stock for Q1 2022, up 10% quarter-over-quarter.
- 68 funds opened new Neurocrine Biosciences positions in Q1 2022 and 43 closed out, a net change of +25 holders.
- The largest Neurocrine Biosciences buyer in Q1 2022 was Polar Capital Holdings, an estimated $61.4M added.
- The largest Neurocrine Biosciences seller in Q1 2022 was Janus Henderson Group, an estimated $96.3M sold.
Based on aggregated 13F filings for Q1 2022.